TO THE EDITOR
Prognosis of acute myeloid leukemia (AML) depends on different factors like age, performance status, tumor mass, but especially on cytogenetic characteristics of the blasts. 1 Inv 16 is supposed to be a favorable prognostic factor, 2 and the majority of patients carrying this chromosome abnormality can be cured with conventional chemotherapy, especially when high dose Ara-C is used. The presence of the Philadelphia chromosome in AML is very rare 3 and it characterizes a group of patients with an unfavorable prognosis. 4 The simultaneous occurrence of numeric and structural aberrations in a leukemic blast is a common finding. To our knowledge we describe here the first case of AML carrying a CBFbeta-MYH11 transcript together with a bcr-abl transcript in the leukemic blast of an AML M1 case.
A 40-year-old female patient was admitted at a local hospital because of intermittent abdominal pain. She reported a slight weight decrease of 6 kg during the last 6 months and increasing fatigue and asthenia in the last 10 days. Physical examination was unremarkable. Routine laboratory findings showed an unexpected elevated white blood cell count (80 000/l) with 85% of blasts. Hemoglobin level was 12 g/dl and the platelet count was 60 000/l.
Blasts were medium-sized and had basophilic cytroplasma with few azurophilic granules. The nucleus showed a fine chromatin, sometimes it was polylobulated and nucleolated.
Cytochemical analysis showed no positive blasts to Period acid Schiff, naphtol ASD chloracetate esterease and alpha naphtol aceate esterase staining, but 20% had a positivity for myeloperoxidase. The morphological and cytochemical analysis referred to an acute myeloid leukemia of the M1 type. The myeloid nature of blasts was confirmed by the cytoplasmatic positivity for myeloperoxidase. No B and T cell-associated markers were found. There was a strong positivity for CD13, CD33, CD34 and CD117. Approximately 50% of the blasts expressed the CD4 antigen. Cytogenetic analysis indicated the simultaneous presence of the Philadelphia chromosome and the pericentric inversion 16 in 18/22 metaphases, whereas in 4/22 metaphases only the inversion 16 was present. RT-PCR analysis confirmed those results. The amplification of the bcr-abl fusion gene revealed a 521 bp fragment, which corresponds to the e1-a2 fusion product. Sequence analysis was completely identical to the published one.
The RT-PCR amplified inv16 transcript showed a 418 bp fragment. Sequence analysis of this product revealed a new and uncommon breakpoint between exon 5 of CBF␤ and exon 12 of the MYH11 gene with the following sequence: CBF b5′CTCATCGGGAGGAAATGGA GGTCCATGAGCTGGA3′MYH11. Although inv16 is the hallmark of AML M4eo, 2 it has been recently shown that the fusion transcript CBF␤-MYH11 is also present in a large number of other acute myeloid leukemias, 5 mainly of the M4 and M5 type. Up to date, only a few cases of M1 with an inv16 have been described. Furthermore, also the rare cases of Philadelphia positive AMLs usually belong to the M4 and M5 subgroup of the FAB classification. 3 This stands in contrast to our case, because morphological and cytochemical analysis showed a M1 type. As described in literature and as found in our case, the corresponding e1-a2 bcr-abl fusion product in AML is identical to the one normally found in B-ALL. 3 Novel CBF␤-MYH11 fusion transcripts are under a continuous debate to be RT-PCR artefacts. 6 We exclude such an RT-PCR-induced artefact in our case for two reasons: first, cytogenetic analysis revealed the presence of inv16 in all analyzed metaphases. Second, we confirmed our RT-PCR by sequence analysis, describing a new and unusual breakpoint. This new type has recently been identified in two cases of AML, but the clinical relevance remains unclear. 7 It is noteworthy to say that in our case both aberrations were found in the blasts at diagnosis, so that therapy-related second aberrations can be excluded, as supposed for other leukemias. 4 Interestingly, both fusion products were not more detectable after one cycle of conventional induction therapy by RT PCR analysis. 
